Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy
Authors
Keywords
-
Journal
Immunotherapy
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2020-06-25
DOI
10.2217/imt-2020-0063
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
- (2019) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
- (2019) Yung-Jue Bang et al. Gastric Cancer
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
- (2019) Ken Kato et al. Future Oncology
- Immunotherapy in Bladder Cancer
- (2019) Venu Madhav Konala et al. AMERICAN JOURNAL OF THERAPEUTICS
- Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)
- (2019) A. Adenis et al. EUROPEAN JOURNAL OF CANCER
- Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
- (2019) Lizza E.L. Hendriks et al. EUROPEAN JOURNAL OF CANCER
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
- (2019) Nicholas D. Klemen et al. Journal for ImmunoTherapy of Cancer
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Check point inhibitors a new era in renal cell carcinoma treatment
- (2018) Mohamed Alsharedi et al. MEDICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
- (2017) Maud Rijnders et al. EUROPEAN UROLOGY
- Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
- (2017) Russell D. Petty et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
- (2016) Young Kwang Chae et al. Clinical Lung Cancer
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
- (2015) Xiangjiao Meng et al. CANCER TREATMENT REVIEWS
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
- (2015) Qin Pan et al. STEM CELLS
- Combined immunotherapy improves survival in metastatic melanoma
- (2015) S. Mayor BMJ-British Medical Journal
- Combined immunotherapy improves survival in metastatic melanoma
- (2015) S. Mayor BMJ-British Medical Journal
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
- (2015) Abhishek D. Garg et al. Frontiers in Immunology
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Immunotherapy: A useful strategy to help combat multidrug resistance
- (2012) Tyler J. Curiel DRUG RESISTANCE UPDATES
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906)
- (2010) Ken Kato et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now